Latest News and Press Releases

CELEBRATION, Fla., Nov. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization...

CELEBRATION, Fla., Oct. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company focused on the discovery, development and commercialization...

SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty...

CELEBRATION, Fla., Sept. 01, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, August 11, 2022, at 5:00 p.m. ET Perry Sternberg, Corium, Inc.’s President and CEO, to Participate and Provide...

CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...

CELEBRATION, Fla., Aug. 04, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...

CELEBRATION, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...

CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and...

Three clinical studies demonstrated serdexmethylphenidate (SDX), KemPharm’s prodrug of d-methylphenidate (d-MPH), yielded significantly lower abuse-related effects compared to d-MPH CELEBRATION,...